Temozolomide
Phase 3Completed 0 watching 0 views this week📈 Rising
72
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Glioblastoma Multiforme
Conditions
Glioblastoma Multiforme
Trial Timeline
Jun 1, 2009 → Mar 1, 2017
NCT ID
NCT00916409About Temozolomide
Temozolomide is a phase 3 stage product being developed by Novocure for Glioblastoma Multiforme. The current trial status is completed. This product is registered under clinical trial identifier NCT00916409. Target conditions include Glioblastoma Multiforme.
Hype Score Breakdown
Clinical
27
Activity
18
Company
5
Novelty
9
Community
10
Clinical Trials (6)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03705351 | Phase 1 | Terminated |
| NCT03477110 | Phase 1 | Completed |
| NCT03232424 | Phase 1 | Completed |
| NCT03780569 | Pre-clinical | UNKNOWN |
| NCT02507232 | Phase 1 | Terminated |
| NCT00916409 | Phase 3 | Completed |
Competing Products
20 competing products in Glioblastoma Multiforme